Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study-Reference-Cited by-同舟云学术

Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study

Published:2013-07-31 Issue:1 Volume:14 Page:
ISSN:1471-2369
Container-title:BMC Nephrology
language:en
Short-container-title:BMC Nephrol

Author:

Prats Merche,Font Ramon,García Carmen,Cabré Carmen,Jariod Manel,Vea Alberto Martinez

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/article/10.1186/1471-2369-14-167/fulltext.html

Reference48 articles.

1. Hsu CY, McCulloch CE, Curhan GC: Iron status and haemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002, 13: 2783-2786. 10.1097/01.ASN.0000034200.82278.DC.

2. Besarab A, Coyne DW: Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010, 6: 699-710. 10.1038/nrneph.2010.139.

3. Macdougall IC: Iron supplementation in the non-dialysis chronic kidney disease(ND-CKD) patients: oral or intravenous?. Curr Med Res Opin. 2010, 26: 473-482. 10.1185/03007990903512461.

4. Vaziri ND: Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis. 2013, 61: 992-1000. 10.1053/j.ajkd.2012.10.027.

5. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y: Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012, 125: 991-999. 10.1016/j.amjmed.2012.01.015.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypophosphorémie après traitement par fer injectable chez l’adulte : comparaison entre le carboxymaltose ferrique et l’hydroxyde ferrique-saccharose;Annales Pharmaceutiques Françaises;2023-09

2. Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series;Transfusion Medicine;2023-06

3. Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease;Renal Failure;2023-01-23

4. Methodology and Baseline Data of a Comparative Exploratory Double-Blinded Randomized Study of Intravenous Iron on Fibroblast Growth Factor 23 and Phosphate in Chronic Kidney Disease;Kidney and Blood Pressure Research;2023

5. Severe hypophosphatemia secondary to chronic treatment with endovenous ferric carboxymaltose;Endocrinología, Diabetes y Nutrición (English ed.);2022-10